PCVX Q4 2021 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena

PCVXVaxcyte, Inc.

$9B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$30M

Net Income

-$29M

EPS (Diluted)

$-0.52

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$51M

Free Cash Flow

-$52M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$324M

Total Liabilities

$40M

Stockholders' Equity

$284M

Cash & Equivalents

$69M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$30M	-$19M	-53.4%
Net Income	-$29M	-$21M	-37.7%